Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of METROPOLIS.NS is 580 and suggests 3.65% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendat